Compare Cardinal Health Inc (CAH) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Nutrien Ltd — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Nutrien Ltd trades at $68.65 (market cap $32.62B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Nutrien Ltd pays the higher dividend (3.21%). Which is the better fit depends on your goals.
| CAH | NTR | |
|---|---|---|
Market Cap | $53.89B | $32.62B |
Sector | Health | Basic Materials |
52-Week High | $239.71 | $83.94 |
52-Week Low | $146.04 | $53.64 |
Enterprise Value | $58.87B | $45.79B |
Dividend Yield | 0.89% | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Nutrien (NTR) trades at $67.60, up 3.32% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 13.77 and net income margin of 8.58%. Recent earnings beat expectations in Q1 2026, and analyst consensus is strongly positive with a $79.50 price target. The company maintains solid cash flow from operations at $4.01 billion despite recent net cash outflows.
NTR presents a compelling value opportunity with reasonable valuation metrics and strong analyst support. Key risks include volatile fertilizer prices and global agricultural demand fluctuations. The upcoming Q2 2026 earnings report with expected EPS of $2.89 represents a significant near-term catalyst for price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
